Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants. The company has a research collaboration agreement with The Rockefeller University to develop treatments for autoimmune diseases. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
OptionableNot Optionable
Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions
What is Hemogenyx Pharmaceuticals' stock symbol?
Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."
Has Hemogenyx Pharmaceuticals been receiving favorable news coverage?
Press coverage about HEMO stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hemogenyx Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Hemogenyx Pharmaceuticals' key competitors?
Some companies that are related to Hemogenyx Pharmaceuticals include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Axovant Sciences (AXGT), Biocure Technology (CURE), Biotest (BIO) and Bioventix (BVXP).
Who are Hemogenyx Pharmaceuticals' key executives?
Hemogenyx Pharmaceuticals' management team includes the folowing people:
- Dr. Vladislav Sandler Ph.D., Co-Founder, CEO & Director
- Ms. Alexis M. Sandler, Co-Founder, COO & Non-Exec. Director
- Mr. Lawrence Pemble, Chief Operating Officer
- Sir Marc Feldmann MB BS, BSc(Med) Hons, PhD, FRCPath, FRCP, FMedSci, Exec. Chairman & Chairman of Advisory Board
- Mr. Andrew Wright, Financial Controller & Company Sec.
How do I buy shares of Hemogenyx Pharmaceuticals?
Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hemogenyx Pharmaceuticals' stock price today?
One share of HEMO stock can currently be purchased for approximately GBX 2.94.
What is Hemogenyx Pharmaceuticals' official website?
MarketBeat Community Rating for Hemogenyx Pharmaceuticals (LON HEMO)
MarketBeat's community ratings are surveys of what our community members think about Hemogenyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe HEMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
